GoAI
Get started
NeuroSense Therapeutics Ltd. logo

NeuroSense Therapeutics Ltd.

NRSN

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$0.3763

+$0.0259 · +7.39%

Aug 21, 4:00 PM ET

NRSN company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

25

Expensive

Momentum

24

Weakening

Sentiment

55

Mixed

Risk resilience

23

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.

Industry
Biotechnology
Sector
Healthcare
Headquarters
IL
CEO
Alon Ben-Noon
Listed since
Dec 9, 2021
Employees
17

Market position

Day range

Current $0.3763

52-week range

Current $0.3763

Open
$0.363
Previous close
$0.3504
Volume
128.46K
0.57× average
Average volume
224.38K
Average daily volume
Market cap
13.3M USD
Beta
1.6
Market reference 1
50-day average
$0.6169
-39.01% below average
200-day average
$0.815
-53.83% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
19.6M USD
EV / EBITDA
-1.76×
Earnings yield
-56.77%
Free cash flow yield
-39.19%

Profitability & efficiency

Return on equity
713.14%
Return on assets
-1082.20%
Return on invested capital
797.48%

Financial health

Current ratio
0.31×

Financial statements

Income trends

Operating income

−11.09M USD-11.95%

Net income

−11.13M USD-8.96%
Income trends across reported periods−3.09M USD−6.89M USD−10.7M USD−14.5M USDOperating income, FY2021: −5.59M USDOperating income, FY2022: −13.55M USDOperating income, FY2023: −12.05M USDOperating income, FY2024: −9.9M USDOperating income, FY2025: −11.09M USDNet income, FY2021: −4.04M USDNet income, FY2022: −12.34M USDNet income, FY2023: −10.11M USDNet income, FY2024: −10.21M USDNet income, FY2025: −11.13M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −5.59M USD. Operating income FY2022 −13.55M USD. Operating income FY2023 −12.05M USD. Operating income FY2024 −9.9M USD. Operating income FY2025 −11.09M USD. Net income FY2021 −4.04M USD. Net income FY2022 −12.34M USD. Net income FY2023 −10.11M USD. Net income FY2024 −10.21M USD. Net income FY2025 −11.13M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Cost of goods sold———89K USD—
Gross profit———−89K USD—
Research and development6.23M USD5.7M USD7.27M USD6.42M USD3.08M USD
Selling, general, and administrative4.86M USD4.2M USD4.78M USD7.05M USD2.51M USD
Operating expenses11.09M USD9.9M USD12.05M USD13.46M USD5.59M USD
Interest income13K USD2K USD178K USD91K USD—
Interest expense—311K USD550K USD15K USD1.15M USD
Depreciation and amortization16K USD22K USD21K USD89K USD3K USD
Operating income−11.09M USD−9.9M USD−12.05M USD−13.55M USD−5.59M USD
Net income−11.13M USD−10.21M USD−10.11M USD−12.34M USD−4.04M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
67%
6 beats, 3 misses, 0 met estimates
Average EPS surprise
-15.66%
9 comparable reports
Latest EPS result
-0.24
Estimate -0.07 · Miss by 231.92%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.04-0.12-0.2-0.27Q4 '24BeatQ2 '25No estimateQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26MissQ2 '26EstimateQ2 '26Estimate
Q4 2024, reported Dec 18, 2024: actual -0.11, estimate -0.16, surprise +31.25%, Beat. Q2 2025, reported Apr 4, 2025: actual -0.083, estimate —, surprise —, Comparison unavailable. Q2 2025, reported Apr 7, 2025: actual -0.06, estimate -0.104, surprise +42.45%, Beat. Q3 2025, reported Aug 1, 2025: actual -0.138, estimate -0.223, surprise +38.14%, Beat. Q4 2025, reported Dec 17, 2025: actual -0.13, estimate -0.044, surprise -197.48%, Miss. Q1 2026, reported Mar 31, 2026: actual -0.235, estimate -0.071, surprise -231.92%, Miss. Q2 2026, reported Apr 6, 2026: actual —, estimate -0.085, surprise —, Comparison unavailable. Q2 2026, reported Jun 30, 2026: actual —, estimate -0.195, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates534.66K438.85K343.05K247.24KQ2 '26EstimateQ2 '26Estimate
Q2 2026, reported Apr 6, 2026: actual —, estimate 514.1K USD, surprise —, Comparison unavailable. Q2 2026, reported Jun 30, 2026: actual —, estimate 267.8K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Recent analyst actions

2 institutions
Maxim GroupdowngradeBuyHold

NRSN news

prnewswire.com

NeuroSense Issues CEO Letter to Shareholders

CAMBRIDGE, Mass., Aug. 13, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

Read source
gurufocus.com

NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada

NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada PR Newswire

Read source
prnewswire.com

NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada

Final meeting minutes reflect alignment with Health Canada on the planned content and structure of the ALS submission CAMBRIDGE, Mass., Aug. 6, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

Read source
prnewswire.com

NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS

The planned submission follows alignment with Health Canada on the NDS pathway and is supported by additional PARADIGM data, including a survival benefit and consistent effects across PrimeC's multi-pathway biomarker…

Read source
prnewswire.com

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward CAMBRIDGE, Mass.

Read source
gurufocus.com

NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS

NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallma

Read source

NRSN peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research NRSN

research.disclaimer